Stay updated on Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma

Sign up to get notified when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The page has updated its date references, removing older dates and adding new ones for March 2025.
    Difference
    0.6%
    Check dated 2025-03-10T23:57:26.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The page has been updated to reflect new trial dates for Ibrutinib and Nivolumab in treating patients with relapsed or refractory classical Hodgkin lymphoma, with the previous dates being replaced by 2025 dates.
    Difference
    2%
    Check dated 2025-03-03T22:22:33.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T18:28:33.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    1%
    Check dated 2025-02-10T09:20:03.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T04:57:59.000Z thumbnail image
  8. Check
    68 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.1%
    Check dated 2025-01-19T19:29:25.000Z thumbnail image

Stay in the know with updates to Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma

Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.